10-Q: Lisata Therapeutics Narrows Q3 Loss, Advances Cancer Drug Certepetide

Lisata Therapeutics reported a reduced net loss in the third quarter of 2025, driven by lower operating expenses, while its lead cancer drug certepetide showed promising clinical results in pancreatic cancer trials and secured new licensing deals.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $13.6 million from $15.4 million in the prior year.
• Operating expenses for the nine months decreased by $2.3 million (12.9%) to $15.2 million, primarily due to lower research and development (R&D) and general and administrative (G&A) costs.
• Cash and cash equivalents increased to $19.0 million as of September 30, 2025, from $16.2 million at December 31, 2024.
• Certepetide demonstrated clinically meaningful improvements in progression-free survival (PFS) and objective response rate (ORR) in Cohort B of the Phase 2b ASCEND trial for metastatic pancreatic ductal adenocarcinoma (mPDAC).
• The company entered into new non-exclusive license agreements with Kuva Labs and Catalent, Inc. for certepetide, potentially generating future milestone payments and royalties.
• Commencement of certain readiness activities for the planned Phase 3 mPDAC study has been delayed to manage capital.
• Additional financing is expected to be needed by the end of 2026 to meet long-term liquidity needs.

Sentiment

Score: 6

Explanation: The company showed improved financial performance with reduced losses and operating expenses, and positive clinical trial data for its lead asset, certepetide, in a challenging indication. New licensing deals also provide future potential. However, the delay in Phase 3 readiness due to capital constraints and the explicit need for additional financing by the end of 2026 temper the positive developments, indicating ongoing financial challenges.

Positives

• Net loss for the nine months ended September 30, 2025, improved to $13.6 million from $15.4 million in the prior year.
• Operating expenses decreased by $2.3 million (12.9%) to $15.2 million for the nine months ended September 30, 2025.
• Research and development expenses decreased by $1.6 million (18.7%) to $6.8 million for the nine months ended September 30, 2025.
• General and administrative expenses decreased by $0.7 million (7.6%) to $8.4 million for the nine months ended September 30, 2025.
• Cash and cash equivalents increased to $19.0 million as of September 30, 2025, from $16.2 million at December 31, 2024.
• Certepetide's Phase 2b ASCEND trial Cohort B showed clinically meaningful improvements: 6-month PFS of 60.8% (certepetide) vs. 25% (placebo), median PFS of 7.5 months (certepetide) vs. 4.7 months (placebo), and ORR of 45.2% (certepetide) vs. 19% (placebo).
• Certepetide demonstrated a benign safety profile in ASCEND Cohorts A and B, similar to placebo.
• Secured a non-exclusive license agreement with Catalent, Inc. for certepetide as an antibody drug conjugate (ADC) payload, with potential development milestones up to $10.5 million.
• Recognized $1.0 million in revenue from an exclusive license agreement with Kuva Labs in November 2024.
• Sold $10.7 million of New Jersey net operating losses (NJ NOLs) for $871 thousand in January 2025, resulting in a $962 thousand deferred income tax benefit.

Negatives

• Total current assets decreased significantly to $21.6 million at September 30, 2025, from $34.6 million at December 31, 2024.
• Total equity decreased to $17.1 million at September 30, 2025, from $29.3 million at December 31, 2024.
• The company has a history of net operating losses and negative cash flows from its operating activities.
• Commencement of certain readiness activities for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC), particularly those related to chemistry, manufacturing and controls (CMC), has been delayed.
• The company expects to need additional financing by the end of 2026 to meet long-term liquidity needs.
• Investment income, net, decreased to $665 thousand for the nine months ended September 30, 2025, from $1,533 thousand in the prior year.
• The company is subject to the "Baby Shelf Limitation" on its At The Market (ATM) offering, limiting the amount it can raise to one-third of its public float (currently $9,855,890).

Risks

• Ability to obtain sufficient capital or strategic business arrangements to fund operations and expansion plans, including clinical trials and commercialization.
• Ability to build and maintain necessary management and human resources infrastructure.
• Whether a market is established for products and ability to capture a meaningful share.
• Scientific, regulatory, and medical developments beyond control.
• Ability to obtain and maintain governmental licenses, accreditations, or certifications, and comply with healthcare laws.
• Whether current or future patent applications result in issued patents, their scope, and ability to commercialize without infringing third-party patents.
• Whether potential strategic or financial benefits of various licensing agreements will be realized.
• Ability to diversify the pipeline of development product candidates, including through acquisitions or other strategic transactions, and whether such efforts will add shareholder value.
• Results of development activities.
• Ability to complete planned clinical trials (or initiate others) in estimated timelines due to patient enrollment delays (novelty of treatment, patient population size, competition, availability, inclusion criteria).
• Extent to which any future public health crisis and its long-term effects may impact business, including clinical trials and financial condition.
• Inability to obtain additional capital could materially and adversely affect business operations.
• Additional equity financing may be dilutive to stockholders.
• Debt financing, if available, may involve significant cash payment obligations and restrictive covenants.
• Stock price may not reach levels necessary to induce option or warrant exercises.
• Asset sales may not be possible on acceptable terms.

Future Outlook

The company believes its current cash on hand is sufficient to fund operating expenses for at least the next 12 months. However, it expects to require additional financing by the end of 2026 to meet long-term liquidity needs, potentially through debt, equity, partnerships, or asset sales. Final data and conclusions from the ASCEND study are anticipated in the first quarter of 2026.

Management Comments

• Our goal is to develop and commercialize products that address important unmet medical needs.
• We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.
• We believe that, as a result [of delaying Phase 3 readiness activities and identifying operating efficiencies], it currently has sufficient cash to meet its funding requirements over the next 12 months.

Industry Context

Lisata Therapeutics operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, specifically targeting solid tumors. Its lead product, certepetide, aims to overcome common challenges in cancer treatment, such as poor drug penetration into dense tumor stroma and immunosuppressive tumor microenvironments. The strategy of co-administering certepetide with existing anti-cancer therapies (chemotherapy, immunotherapy, ADCs) positions it as an enhancer of current treatments, potentially offering a faster path to market compared to developing new chemical entities. The focus on mPDAC, a notoriously difficult-to-treat cancer, highlights the significant unmet medical need the company is addressing. Recent collaborations with Catalent for ADC payloads align with a growing trend in oncology to develop more targeted and potent therapies.

Comparison to Industry Standards

• The ASCEND trial Cohort B results for mPDAC (median PFS 7.5 months, ORR 45.2%) show a clinically meaningful improvement over placebo (median PFS 4.7 months, ORR 19%). This is a positive signal in a disease area where treatment options are limited and survival rates are generally poor. For context, standard gemcitabine/nab-paclitaxel regimens typically show median PFS in the range of 5-6 months and ORR around 20-30% in first-line mPDAC. Certepetide's results appear to be at the higher end or exceeding these benchmarks for combination therapy.
• The company's strategy of co-administration to avoid creating new chemical entities (NCEs) is a common approach to accelerate development and regulatory pathways, contrasting with companies developing novel standalone NCEs which face longer and more complex development cycles.
• The collaboration with Catalent on Antibody Drug Conjugates (ADCs) positions Lisata within a rapidly evolving and high-value segment of oncology, where companies like Seagen (now Pfizer) and Daiichi Sankyo have demonstrated significant success with ADC platforms. Certepetide's potential to enhance ADC delivery could be a differentiator.

Management Changes

Corporate Governance

Legal Proceedings

• Settled a lawsuit with Lingmed Limited on March 25, 2024, for $0.5 million cash payment and 5.0% of any future milestone payments received under the Qilu Agreement, plus an additional $250 thousand for the first future milestone. The action was dismissed with prejudice on April 9, 2024.
• No other material legal proceedings are currently ongoing.

Related Party Transactions

• The company owns 38.6% of Impilo Therapeutics as of September 30, 2025, and had previously expensed investments in Impilo under the equity method of accounting.
• At the time of the Sanford Burnham Prebys (SBP) license agreement in December 2015, Cend's founding shareholder was an executive at SBP. SBP did not own shares of the company's common stock as of September 30, 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises; positive clinical data could increase share value; ongoing losses and capital needs pose risks.
• Employees: Executive compensation adjustments and clarifications to severance packages provide clarity and potentially improved benefits for key personnel.
• Customers/Patients: Certepetide's promising clinical results offer hope for improved treatment options for solid tumors, particularly metastatic pancreatic cancer.
• Partners (Qilu, Kuva, Catalent): Continued collaboration and potential for milestone payments and royalties based on successful development and commercialization.
• Creditors: The need for future financing and existing operating losses indicate potential reliance on debt or equity, which could impact creditworthiness.

Next Steps

• Final data and conclusions of the ASCEND study are anticipated to be available in the first quarter of 2026.
• The company will continue to identify operating efficiencies.
• The company expects to need additional financing by the end of 2026.
• The company will continue to seek grants for scientific and clinical studies from governmental agencies and foundations.
• Catalent has agreed to grant the company a right of first negotiation for a license if Catalent initiates an out-licensing process for an asset resulting from their agreement.

Key Dates

Recommendation

The company presents a mixed financial and operational picture. While the reduced net loss, lower operating expenses, and positive clinical data for certepetide in mPDAC are encouraging, the significant decrease in total current assets and equity, coupled with the explicit delay in Phase 3 readiness due to capital constraints and the stated need for additional financing by the end of 2026, indicate ongoing financial fragility. The new licensing deals offer future potential but are not immediate revenue drivers. For a seasoned investor, the clinical progress is a strong positive, but the persistent capital needs and the delay in advancing to a pivotal Phase 3 trial introduce considerable risk. A "hold" recommendation reflects the potential upside from clinical success and partnerships, balanced against the substantial financial risks and the uncertainty of future capital raises on favorable terms. Investors should monitor financing activities and further clinical trial progress closely.

Keywords

Certepetide, Solid Tumors, Pancreatic Cancer, mPDAC, Oncology, Clinical Stage, Biopharmaceutical, CendR Pathway, Antibody Drug Conjugates (ADCs), Clinical Trials, SEC Filing, LSTA, Biotech, Drug Development